Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-04-14

Clinical Trial Update: A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial comparing tirzepatide to dulaglutide in adults with type 2 diabetes has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dulaglutide (dulaglutide)
  • Tirzepatide (tirzepatide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2022-04-14